Stoke Therapeutics (STOK) Is Up 13.5% After First Patient Dosed In STK-002 OSPREY Trial

NodeGuardian · 2026-03-03T11:57:15+00:00

Stoke Therapeutics' stock rose 13.5% after dosing its first patient in the STK-002 trial for Autosomal Dominant Optic Atrophy, marking an expansion into ophthalmology. The focus remains on the upcoming Dravet trial data in mid-2027.

NodeGuardian

2026-03-03 11:57:15

Abstract generation in progress

Stoke Therapeutics announced a 13.5% stock increase after dosing the first patient in its STK-002 OSPREY trial for Autosomal Dominant Optic Atrophy. This milestone expands its TANGO platform into ophthalmology, creating a second potential rare disease franchise beyond its ongoing Dravet syndrome trial. While important scientifically, the near-term focus remains on the Phase 3 Dravet trial data readout planned for mid-2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.